Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (9)	2/9/2005 12:06:22 PM
From: tuck	Read Replies (1) \| Respond to of 166

"And alny is up on this news?" Why not? Plausible approach to the delivery issues associated with RNAi and antisense, and no one else in the field seems to have considered it. Differentiates them. Are you incredulous because financial terms aren't mentioned, and it's going up on a tough day? The stock has had a mo feel to it after publishing that paper on systemic in vivo delivery a few months back: Message 20754908 We've been banging the drum about delivery being the stumbling block for RNAi, and ALNY seems to be addressing the issue head on. Cheers, Tuck